PATENT CLAIM ANALYSIS

Application Number: 16401385
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-11
Patent Classification: ["424", "427000"]

Abstract:
A method of treating or inhibiting degeneration of a retina of a subject in need thereof comprising administering an effective amount of a compound of metipranolol, or a metabolite thereof, to an organ, a tissue, or the subject, wherein the degeneration of the retina is caused by an ocular disease. In some embodiments, the compound, or a metabolite thereof, is administered topically, orally, or parenterally. In some embodiments, a drug delivery vehicle comprising a dosage of the compound, or the metabolite of, is delivered parenterally via intravitreal injection. In further embodiments, the dosage may range from 0.5 μg/day-15 μg/day.

Claim (Index 1):
A method of treating or inhibiting degeneration of a retina of a subject in need thereof comprising administering an effective amount of a compound of metipranolol, or a metabolite thereof, to an organ, a tissue, or the subject, wherein the degeneration of the retina is caused by an ocular disease selected from the group consisting of diabetic retinopathy, choroidal neovascularization, and retinitis pigmentosa.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 100.0
- Lexical Diversity: 2.12727
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15288214', '16171837', '14934810', '12681516', '12429650']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.726593076686216
- 35 USC 102 Novelty (BERT): 0.513776716927146
- Combined Prediction Score: 0.7053114407103089
- Mean Citation Score: 295.4781260000001
- Max Citation Score: 308.17484
- Similarity Product: 232.1720080266905

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test